Marshall Wace, LLP Delcath Systems, Inc. Transaction History
Marshall Wace, LLP
- $77.3 Billion
- Q3 2024
A detailed history of Marshall Wace, LLP transactions in Delcath Systems, Inc. stock. As of the latest transaction made, Marshall Wace, LLP holds 90,908 shares of DCTH stock, worth $880,898. This represents 0.0% of its overall portfolio holdings.
Number of Shares
90,908
Previous 92,731
1.97%
Holding current value
$880,898
Previous $776,000
5.67%
% of portfolio
0.0%
Previous 0.0%
Shares
7 transactions
Others Institutions Holding DCTH
# of Institutions
73Shares Held
7.62MCall Options Held
198KPut Options Held
41.7K-
Aigh Capital Management LLC Baltimore, MD1.78MShares$17.3 Million6.51% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.11MShares$10.8 Million0.0% of portfolio
-
Vivo Capital, LLC Palo Alto, CA997KShares$9.66 Million1.32% of portfolio
-
Essex Investment Management CO LLC Boston, MA337KShares$3.26 Million0.57% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny312KShares$3.02 Million0.0% of portfolio
About DELCATH SYSTEMS, INC.
- Ticker DCTH
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Devices
- Shares Outstandng 8,597,680
- Market Cap $83.3M
- Description
- Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling syste...